Anti-Alpha-synuclein (phospho S129) antibody [P-syn/81A] (Ab184674)

NACP, PARK1, SNCA, Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor

反应种属:Human
抗原名称:SNCA phospho S129
应用:IHC

详细信息

免疫原Synthetic Peptide within Human SNCA phospho S129 aa 100-150 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information. P37840
宿主/亚型Mouse / IgG2a
抗体类型Monoclonal
产品形式Liquid
纯化方式Affinity purification
储存缓冲液Preservative: 0.09% Sodium azide Constituents: PBS
储存条件运输条件: Blue Ice 推荐的短期储存时间: 1-2 weeks 推荐的短期储存条件: +4°C 推荐的长期储存条件: -20°C 储存信息: Avoid freeze / thaw cycle
无载体蛋白No

背景信息

Anti-Alpha-synuclein (phospho S129) antibody [P-syn/81A] (ab184674) is a mouse monoclonal antibody and is validated for use in IHC-P in human, mouse, rat samples. Anti-Alpha-synuclein (phospho S129) antibody [P-syn/81A] (ab184674) has been cited over 31 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality validation processes ensure Anti-Alpha-synuclein (phospho S129) antibody [P-syn/81A] (ab184674) has high sensitivity and specificity. Anti-Alpha-synuclein (phospho S129) antibody [P-syn/81A] (ab184674) specifically detects Alpha-synuclein Phospho-S129 (Phospho-α-synuclein Ser129) (UniProt ID: P37840; Molecular weight: 14kDa) and is sold in 50 µL selling sizes. Alpha-synuclein phosphorylated at serine 129 (NACP/SNCA pS129) is a post-translational modification of the alpha-synuclein protein, which is involved in synaptic function. Elevated levels of pS129 are found in the brains of individuals with Parkinson's disease and related disorders. This modification is linked to the aggregation of alpha-synuclein into Lewy bodies, which are pathological features of these diseases. Research suggests that pS129 may enhance the neurotoxic effects of alpha-synuclein, playing a critical role in the development and progression of neurodegenerative conditions.

文献引用 (60)

Inhibition of de novo ceramide synthesis mitigates alpha-synuclein pathology in a Parkinson's disease mouse model.

抑制从头合成神经酰胺可减轻帕金森病小鼠模型中的α-突触核蛋白病理。

Lee Eunkyung, Park Moon-Young, Park Minkuk, Kim Na-Yeong, Wei Shibo, Hwang Nahee, Ryu Dongryeol, Ryu Hoon, Park Dohyun, Lee Gakyung, Oh Chang-Myung

Pathological α-synuclein elicits granulovacuolar degeneration independent of tau.

病理性α-突触核蛋白可引起与tau蛋白无关的颗粒空泡变性

Dues Dylan J, Erb Madalynn L, Kasen Alysa, Vatsa Naman, Williams Erin T, Nguyen An Phu Tran, Henderson Michael X, Moore Darren J

LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies.

LRRK2 激酶介导溶酶体相关磷酸化 Rabs 在 tau 蛋白病和突触核蛋白病中的积累。

Buck Silas A, Malankhanova Tuyana, Strader Samuel, Ma Eileen B, Yim Sarah, Pratt Harrison W, Ervin John, Lee Edward B, Wang Shih-Hsiu J, Cohen Todd J, West Andrew B, Sanders Laurie H

Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson's disease.

帕金森病 Atp13a2 基因敲除大鼠模型的表型特征分析。

Kinet Rémi, Sikora Joanna, Arotcarena Marie-Laure, Decourt Melina, Balado Eric, Doudnikoff Evelyne, Bohic Sylvain, Vesnaver Marta, Lovisotto Anna, Thiolat Marie-Laure, Dutheil Nathalie, Mazzocco Claire, Harhouri Karim, Steinschneider Rémy, Menoret Severine, Tesson Laurent, Anegon Ignacio, Morari Michele, Vila Miquel, Georges François, Bezard Erwan, Fernagut Pierre-Olivier, Dehay Benjamin

The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.

纯合LRRK2.p.N1437D点突变小鼠是一种新型帕金森病模型

Gan Lin-Hua, Sun Yi-Min, Zhou Xin-Yue, Qi Zhi-Yuan, Liu Feng-Tao, Tang Yi-Lin, Yu Wen-Bo, Xiao Bao-Guo, Wang Jian, Wu Jian-Jun

Templating of monomeric alpha-synuclein results in inflammation and SNpc dopamine neuron death in a genetic mouse model of induced synucleinopathy.

在诱导突触核蛋白病的基因小鼠模型中,单体α-突触核蛋白的模板化会导致炎症和黑质致密部多巴胺神经元死亡

Byrne Matthew D, Petramfar Peyman, Lee Jae-Kyung, Smeyne Richard Jay

Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor function.

向大鼠纹状体内注射α-突触核蛋白预成型原纤维会导致左旋多巴可逆的感觉运动障碍和非运动功能改变

Fleming Sheila M, Scott Sophia, Hamad Edward J, Herman Danielle E, Holden John G, Yan Lily, Linning-Duffy Katrina, Kemp Christopher J, Patterson Joseph R, Miller Kathryn M, Kubik Michael, Kuhn Nathan, Stoll Anna C, Duffy Megan F, Steece-Collier Kathy, Cole-Strauss Allyson, Lipton Jack W, Luk Kelvin C, Sortwell Caryl E

Reliability and modeling of digital histological measurements in Alzheimer's disease neuropathologic change and Lewy body disease.

阿尔茨海默病神经病理学变化和路易体病数字组织学测量的可靠性和建模

Kim Yongya, Andreasson Thea, Vishupad Namitha, Benegal Avani, Pizzo Donald, Hansen Lawrence, Hiniker Annie, Coughlin David

Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.

tau蛋白病中LRRK2相关磷酸化Rab12退行性溶酶体的积累

Buck Silas A, Malankhanova Tuyana, Ma Eileen B, Yim Sarah, Pratt Harrison W, Ervin John, Wang Shih-Hsiu J, Cohen Todd J, West Andrew B, Sanders Laurie H

OTUD5 Protects Dopaminergic Neurons by Promoting the Degradation of α-Synuclein in Parkinson's Disease Model

OTUD5通过促进帕金森病模型中α-突触核蛋白的降解来保护多巴胺能神经元

Xiaomeng Song, Tengfei Liu, Lu Yu, Qiuran Ji, Xin Guo, Runzhe Zong, Yiquan Li, Gan Huang, Qidi Xue, Qingyi Fu, Bingyu Liu, Yi Zheng, Lin Chen, Chengjiang Gao, Huiqing Liu
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6